Literature DB >> 25179215

Baseline screening tools as indicators for symptom outcomes and health services utilization in a collaborative care model for depression in primary care: a practice-based observational study.

Nathan D Shippee1, Brooke H Rosen2, Kurt B Angstman3, Manuel E Fuentes4, Ramona S DeJesus5, Steven M Bruce3, Mark D Williams6.   

Abstract

OBJECTIVE: Within a practice-based collaborative care program for depression, we examined associations between positive baseline screens for comorbid mental and behavioral health problems, depression remission and utilization after 1 year.
METHODS: This observational study of 1507 depressed adults examined baseline screens for hazardous drinking (Alcohol Use Disorders Identification Test score ≥ 8), severe anxiety (Generalized Anxiety Disorder 7-item score ≥ 15) and bipolar disorder [Mood Disorders Questionnaire (MDQ) positive screen]; 6-month depression remission; primary care, psychiatric, emergency department (ED) and inpatient visits 1 year postbaseline; and multiple covariates. Analyses included logistic and zero-inflated negative binomial regression.
RESULTS: At unadjusted baseline, 60.7% had no positive screens beyond depression, 31.5% had one (mostly severe anxiety), 6.6% had two and 1.2% had all three. In multivariate models, positive screens reduced odds of remission versus no positive screens [e.g., one screen odds ratio (OR) = 0.608, p = .000; all three OR = 0.152, p = .018]. Screening positive for severe anxiety predicted more postbaseline visits of all types; severe anxiety plus hazardous drinking predicted greater primary care, ED and inpatient; severe anxiety plus MDQ and the combination of all three positive screens both predicted greater psychiatric visits (all p < .05). Regression-adjusted utilization patterns varied across combinations of positive screens.
CONCLUSIONS: Positive screens predicted lower remission. Severe anxiety and its combinations with other positive screens were common and generally predicted greater utilization. Practices may benefit from assessing collaborative care patients presenting with these screening patterns to determine resource allocation.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anxiety; Collaborative care; Depression; Mental and behavioral health screening tools; Utilization

Mesh:

Year:  2014        PMID: 25179215     DOI: 10.1016/j.genhosppsych.2014.06.014

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  5 in total

1.  Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys.

Authors:  R C Kessler; N A Sampson; P Berglund; M J Gruber; A Al-Hamzawi; L Andrade; B Bunting; K Demyttenaere; S Florescu; G de Girolamo; O Gureje; Y He; C Hu; Y Huang; E Karam; V Kovess-Masfety; S Lee; D Levinson; M E Medina Mora; J Moskalewicz; Y Nakamura; F Navarro-Mateu; M A Oakley Browne; M Piazza; J Posada-Villa; T Slade; M Ten Have; Y Torres; G Vilagut; M Xavier; Z Zarkov; V Shahly; M A Wilcox
Journal:  Epidemiol Psychiatr Sci       Date:  2015-02-27       Impact factor: 6.892

Review 2.  Screening and brief intervention for unhealthy substance use in patients with chronic medical conditions: a systematic review.

Authors:  Christine Timko; Calvin Kong; Lisa Vittorio; Michael A Cucciare
Journal:  J Clin Nurs       Date:  2016-05-03       Impact factor: 3.036

3.  Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.

Authors:  Michael S Broder; Eunice Chang; Dorothy Romanus; Dasha Cherepanov; Maureen P Neary
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

4.  Bipolar Disorder in Primary Care: Integrated Care Experiences.

Authors:  Joseph M Cerimele; John S Kern
Journal:  Focus (Am Psychiatr Publ)       Date:  2017-07-18

Review 5.  Depression sum-scores don't add up: why analyzing specific depression symptoms is essential.

Authors:  Eiko I Fried; Randolph M Nesse
Journal:  BMC Med       Date:  2015-04-06       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.